10 Most Shorted Stocks That Are Loved by Analysts

1. Verve Therapeutics, Inc. (NASDAQ:VERV)

Short Interest Percentage: 29.26%

Average Share Price Target: $27.13

Share Price Upside: 431.96%

Verve Therapeutics, Inc. (NASDAQ:VERV) is a biotechnology company developing treatments for heart diseases. The firm’s thesis revolves around its VERVE-101 drug that turns off a gene in the liver to reduce cholesterol. Its shares jumped by 21% in February when the firm shared that the drug was being evaluated in a Phase 1b trial. Its shares had tanked by 30% last year after the drug presented safety concerns, and this was also the case in April 2024. In April, Verve Therapeutics, Inc. (NASDAQ:VERV)’s stock tanked by 35% when it paused early stage enrollment for the trial after a patient exhibited severe adverse effects which included low platelets. Since then, the shares have been lackluster, and enrollment in the trials remains paused.

Verve Therapeutics, Inc. (NASDAQ:VERV) has focused its attention on the VERVE-102 treatment since then. This also led Jefferies to cut the share price target to $28 from $31 from May 2024 and keep a Buy rating on the shares. Data from VERVE-102 should be available next year, and consequently, any potential deals with Verve Therapeutics, Inc. (NASDAQ:VERV)’s mega pharma partner Eli Lilly is stretched out in the future.

While VEEV has a high analyst share price target upside, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than VEEV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.

Disclosure: None.